Literature DB >> 20084383

[Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

L-C Horn1, K Schierle, D Schmidt, U Ulrich, A Liebmann, C Wittekind.   

Abstract

Numerous recent studies of endometrial and cervical carcinomas as well as malignant mixed müllerian tumors (MMMT) of the uterus have made a revision of the FIGO/TNM classification necessary, effective as of January 1st, 2010. There will be a new subclassification of carcinoma of the uterine cervix with proximal vaginal infiltration, using the same cut-off for the tumor extension as used for stage FIGOIB/T1b (≤/>4 cm), resulting in stage FIGO IIA1/T2a1 and FIGO IIA2/T2a2. In endometrial carcinoma, the previous FIGO IA/pT1a and FIGO IB/pT1b will be merged to FIGO IA/pT1a. The former category FIGO IC/T1c will be changed into FIGO IB/T1b. The category FIGO IC/pT1c will not longer been used. Additionally, there will be no separate classification for the involvement of the endocervical glands by endometrial carcinoma. This feature will be incorporated in stage FIGO I/T1 disease. The new category FIGO II/T2 will be defined as endocervical stromal involvement. There will be a new category, termed T3c/IIIC, which includes regional lymph node involvement. Stage T3c1/IIIC1 will be defined as pelvic lymph node involvement and stage T3c2/IIIC2 para-aortal lymph node involvement with or without pelvic lymph node disease. In the TNM system, regional lymph node involvement can alternatively be classified as N1. The MMMT will be staged like endometrial carcinoma.

Entities:  

Mesh:

Year:  2011        PMID: 20084383     DOI: 10.1007/s00292-010-1273-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  26 in total

1.  The prognostic significance of peritoneal cytology for stage I endometrial cancer.

Authors:  D A Turner; D M Gershenson; N Atkinson; N Sneige; A T Wharton
Journal:  Obstet Gynecol       Date:  1989-11       Impact factor: 7.661

2.  Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  M A Quinn; J L Benedet; F Odicino; P Maisonneuve; U Beller; W T Creasman; A P M Heintz; H Y S Ngan; S Pecorelli
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

3.  [New FIGO staging for uterine sarcomas].

Authors:  L-C Horn; D Schmidt; C Fathke; U Ulrich
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

4.  Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals.

Authors:  W T Creasman; P J Disaia; J Blessing; R H Wilkinson; W Johnston; J C Weed
Journal:  Am J Obstet Gynecol       Date:  1981-12-15       Impact factor: 8.661

5.  Practice patterns of SGO members for stage IIIA endometrial cancer.

Authors:  Christine M Lee; Brian M Slomovitz; Marilyn Greer; Sheena Sharma; Mary Ann Gregurich; Thomas Burke; Karen H Lu; Lois M Ramondetta
Journal:  Gynecol Oncol       Date:  2005-07       Impact factor: 5.482

6.  Prognostic value of peritoneal cytology in endometrial carcinoma.

Authors:  R N Grimshaw; W C Tupper; R C Fraser; M G Tompkins; J F Jeffrey
Journal:  Gynecol Oncol       Date:  1990-01       Impact factor: 5.482

7.  [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].

Authors:  L-C Horn; M Dallacker; K Bilek
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

8.  Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study.

Authors:  R C Boronow; C P Morrow; W T Creasman; P J Disaia; S G Silverberg; A Miller; J A Blessing
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

9.  Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.

Authors:  Edgar Petru; Hans-Joachim Lück; Gavin Stuart; David Gaffney; David Millan; Ignace Vergote
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-02-04       Impact factor: 2.435

10.  Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus.

Authors:  T Kasamatsu; T Onda; N Katsumata; M Sawada; T Yamada; R Tsunematsu; K Ohmi; Y Sasajima; Y Matsuno
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  7 in total

Review 1.  [The 2019 FIGO classification for cervical carcinoma-what's new?]

Authors:  L-C Horn; C E Brambs; S Opitz; U A Ulrich; A K Höhn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 2.  [Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting].

Authors:  Lars-Christian Horn; Anne Kathrin Höhn; Monika Hampl; Grit Mehlhorn; Markus Follmann; Hans-Georg Schnürch
Journal:  Pathologe       Date:  2021-02       Impact factor: 1.011

3.  Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018).

Authors:  Hans-Georg Schnürch; Sven Ackermann; Celine D Alt-Radtke; Lukas Angleitner; Jana Barinoff; Matthias W Beckmann; Carsten Böing; Christian Dannecker; Tanja Fehm; Rüdiger Gaase; Paul Gass; Marion Gebhardt; Friederike Gieseking; Andreas Günthert; Carolin C Hack; Peer Hantschmann; Lars Christian Horn; Martin C Koch; Anne Letsch; Peter Mallmann; Bernhard Mangold; Simone Marnitz; Grit Mehlhorn; Kerstin Paradies; Michael J Reinhardt; Reina Tholen; Uwe Torsten; Wolfgang Weikel; Linn Wölber; Monika Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-07-16       Impact factor: 2.915

4.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

5.  Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Authors:  Linda Hertlein; Johanna Rath; Christine Zeder-Göss; Sophie Fürst; Daniela Bayer; Fabian Trillsch; Sven Mahner; Alexander Burges; Udo Jeschke
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

6.  The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.

Authors:  Annika Stiasny; Christoph P Freier; Christina Kuhn; Sandra Schulze; Doris Mayr; Christoph Alexiou; Christina Janko; Irmi Wiest; Christian Dannecker; Udo Jeschke; Bernd P Kost
Journal:  Oncol Lett       Date:  2017-08-14       Impact factor: 2.967

7.  Expression of Angiopoietin and VEGF in Cervical Cancer and its Clinical Significance.

Authors:  Qingyuan Lv; Weijuan Zhong; Xiabin Ye; Yang Lv; Haiying Liu; Guizhen Yan; Diwen Chen
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.